XML 45 R35.htm IDEA: XBRL DOCUMENT v3.23.2
Commitments and contingencies - Neurocrine Collaboration Agreement - (Details)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended
Jan. 08, 2023
USD ($)
item
Program
$ / shares
shares
Feb. 28, 2023
USD ($)
Program
item
$ / shares
shares
Mar. 31, 2019
Jun. 30, 2023
USD ($)
item
Mar. 31, 2023
USD ($)
Jun. 30, 2022
USD ($)
Jun. 30, 2023
USD ($)
Jun. 30, 2022
USD ($)
Dec. 31, 2022
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Purchase of common stock         $ 31,121        
Allocation of Transaction Price                  
Deferred revenue, current       $ 31,666     $ 31,666   $ 59,377
Deferred revenue, non-current       51,383     51,383   $ 6,450
Neurocrine                  
Allocation of Transaction Price                  
Revenue recognized             689    
Deferred revenue       73,731     73,731    
Neurocrine Collaboration Agreement | Neurocrine                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Upfront payment   $ 136,000              
Purchase of common stock, shares | shares   4,395,588              
Purchase of common stock   $ 7,900              
Termination period     10 years            
Period of advance notice for termination prior to first commercial sale     180 days            
Period of advance notice for termination after first commercial sale     1 year            
Period of advance notice for termination after complete readout of clinical trial     30 days            
Discount related to equity investment   39,000              
Allocation of Transaction Price                  
Allocation of variable consideration       5,859     5,859    
Allocation of fixed consideration   $ 143,900   143,880     143,880    
Costs to obtain collaboration agreement       400     400    
Neurocrine Collaboration Agreement | Neurocrine | Maximum                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Percentage of reduction in royalty payments     50.00%            
Neurocrine Collaboration Agreement | Neurocrine | GBA1                  
Allocation of Transaction Price                  
Allocation of variable consideration       5,361     5,361    
Allocation of fixed consideration       69,459     69,459    
Neurocrine Collaboration Agreement | Neurocrine | Discovery program 1                  
Allocation of Transaction Price                  
Allocation of variable consideration       166     166    
Allocation of fixed consideration       24,807     24,807    
Neurocrine Collaboration Agreement | Neurocrine | Discovery program 2                  
Allocation of Transaction Price                  
Allocation of variable consideration       166     166    
Allocation of fixed consideration       24,807     24,807    
Neurocrine Collaboration Agreement | Neurocrine | Discovery program 3                  
Allocation of Transaction Price                  
Allocation of variable consideration       166     166    
Allocation of fixed consideration       24,807     24,807    
Neurocrine Collaborative Agreement 2019 | Neurocrine                  
Allocation of Transaction Price                  
Revenue recognized       1,600   $ 700 3,600 $ 1,400  
Neurocrine Collaborative Agreement 2023                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Percentage of profit or loss under co-co option 50.00%                
Percentage of development costs incurred 50.00%                
Neurocrine Collaborative Agreement 2023 | Neurocrine                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Number of discovery programs | Program 3                
Percentage of profit or loss under co-co option 50.00%                
Percentage of development costs incurred 50.00%                
Purchase of common stock, shares | shares 4,395,588 4,395,588              
Purchase of common stock $ 39,000 $ 39,000              
Price per share | $ / shares $ 8.88 $ 8.88              
Contract expense             200    
Allocation of Transaction Price                  
Reimbursement costs expected to be received             5,900    
Revenue recognized         $ 69,500        
Deferred revenue, current       26,100     26,100    
Deferred revenue, non-current       47,600     47,600    
Deferred revenue       73,700     $ 73,700    
Number of products | item 4                
Neurocrine Collaborative Agreement 2023 | Neurocrine | GBA1                  
Allocation of Transaction Price                  
Revenue recognized       $ 2,200          
Neurocrine Collaborative Agreement 2023 | Neurocrine | Discovery Programs 2023                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Number of discovery programs | item       3          
Allocation of Transaction Price                  
Revenue recognized       $ 700          
Neurocrine Collaborative Agreement 2023 | Neurocrine | Development milestone                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Number of discovery programs | Program   3              
Neurocrine Collaborative Agreement 2023 | Neurocrine | Development milestone | GBA1                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Aggregate maximum milestone payments to be received from collaborative partner   $ 985,000              
Neurocrine Collaborative Agreement 2023 | Neurocrine | Development milestone | Discovery Programs 2023                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Aggregate maximum milestone payments to be received from collaborative partner   175,000              
Neurocrine Collaborative Agreement 2023 | Neurocrine | Commercial Milestone | GBA1                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Per Milestone, maximum milestone payments to be received from collaborative partner   $ 950,000              
Allocation of Transaction Price                  
Number of products | item   2              
Neurocrine Collaborative Agreement 2023 | Neurocrine | Commercial Milestone | Discovery Programs 2023                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Per Milestone, maximum milestone payments to be received from collaborative partner   $ 275,000              
Allocation of Transaction Price                  
Number of products | item   1